Production (Stage)
Allogene Therapeutics, Inc.
ALLO
$1.06
-$0.03-2.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | -- | 22.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | -- | 22.00K |
| Cost of Revenue | 50.20M | 44.97M | 44.71M | 50.36M | 52.26M |
| Gross Profit | -50.20M | -44.97M | -44.71M | -50.36M | -52.24M |
| SG&A Expenses | 14.99M | 15.52M | 16.33M | 16.09M | 17.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.19M | 60.49M | 61.05M | 66.44M | 69.53M |
| Operating Income | -65.19M | -60.49M | -61.05M | -66.44M | -69.50M |
| Income Before Tax | -59.73M | -59.50M | -66.29M | -66.36M | -65.00M |
| Income Tax Expenses | -- | 443.00K | -- | -- | -- |
| Earnings from Continuing Operations | -59.73M | -59.94M | -66.29M | -66.36M | -65.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.73M | -59.94M | -66.29M | -66.36M | -65.00M |
| EBIT | -65.19M | -60.49M | -61.05M | -66.44M | -69.50M |
| EBITDA | -62.09M | -57.26M | -57.84M | -62.80M | -65.95M |
| EPS Basic | -0.28 | -0.28 | -0.32 | -0.35 | -0.38 |
| Normalized Basic EPS | -0.17 | -0.17 | -0.17 | -0.20 | -0.24 |
| EPS Diluted | -0.28 | -0.28 | -0.32 | -0.35 | -0.38 |
| Normalized Diluted EPS | -0.17 | -0.17 | -0.17 | -0.20 | -0.24 |
| Average Basic Shares Outstanding | 215.36M | 210.57M | 209.19M | 190.03M | 169.13M |
| Average Diluted Shares Outstanding | 215.36M | 210.57M | 209.19M | 190.03M | 169.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |